Bitcoin experienced renewed pressure following the release of US economic data showing the annual Consumer Price Index (CPI) rose 3.7%, slightly above the forecasted 3.6%, and retail sales increased by 0.8%, surpassing estimates. These figures led markets to reconsider the Federal Reserve's interest rate strategy, with a 75% chance of rates remaining steady in October but growing expectations for a hike before year-end. Despite the short-term challenges, the data does not suggest a fundamentally bearish outlook for Bitcoin. Trading is likely to remain range-bound and influenced by upcoming economic reports as investors watch for signs of easing inflation or weaker economic growth.
Bitcoin's near-term outlook is influenced by US economic data, with markets pricing in a 75% chance of steady interest rates in October but a hike likely before year-end. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 17, 2026 01:31 WIB: out of 50 major cryptocurrencies, 19 rose and 30 fell. Notable movers include CRV at Rp6.181 with 79% sell activity, UNI at Rp128.298 with 66% buy activity, and ADA at Rp4.002 with 86% buy activity.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
